

WEST VIRGINIA LEGISLATURE

2017 REGULAR SESSION

Committee Substitute

for

Committee Substitute

for

Senate Bill 333

BY SENATORS TAKUBO, PALUMBO, STOLLINGS, ROMANO,

CLINE AND MARONEY

[Originating in the Committee on the Judiciary;

reported on March 25, 2017]

1 A BILL to amend and reenact §60A-9-4, §60A-9-5 and §60A-9-5a of the Code of West Virginia,
2 1931, as amended; and to amend said code by adding thereto a new section, designated
3 §60A-9-9, all relating to the Controlled Substances Monitoring Program database;
4 requiring reporting instances of an overdose or a suspected overdose to the database;
5 setting out elements to be reported; allowing access to the database to deans of the state's
6 medical schools or their designees for monitoring prescribing practices of prescribing
7 faculty and residents; allowing access to designated physician reviewers for medical
8 provider employers and hospital chief medical officers; allowing the Board of Pharmacy to
9 require that drugs of concern be reported to the database; exempting reporting
10 requirements for drugs of concern from criminal penalties; allowing agents for the Office
11 of Health Facility Licensure and Certification to access the database; allowing the Board
12 of Pharmacy to develop administrative penalties for not reporting drugs of concern;
13 providing for rulemaking; requiring the licensing boards to report to the Board of Pharmacy
14 when notified of unusual prescribing habits of a licensee; and making technical
15 corrections.

Be it enacted by the Legislature of West Virginia:

1 That §60A-9-4, §60A-9-5 and §60A-9-5a of the Code of West Virginia, 1931, as amended,
2 be amended and reenacted; and that said code be amended by adding thereto a new section,
3 designated §60A-9-9, all to read as follows:

ARTICLE 9. CONTROLLED SUBSTANCES MONITORING.

§60A-9-4. Required information.

1 (a) Whenever a medical services provider dispenses a controlled substance listed in
2 Schedule II, III or IV as established under the provisions of article two of this chapter or an opioid
3 antagonist, or whenever a prescription for the controlled substance or opioid antagonist is filled
4 by: (i) A pharmacist or pharmacy in this state; (ii) a hospital, or other health care facility, for
5 outpatient use; or (iii) a pharmacy or pharmacist licensed by the Board of Pharmacy, but situated

6 outside this state for delivery to a person residing in this state, the medical services provider,
7 health care facility, pharmacist or pharmacy shall, in a manner prescribed by rules promulgated
8 by the ~~board~~ under Board of Pharmacy pursuant to this article, report the following information,
9 as applicable:

10 (1) The name, address, pharmacy prescription number and Drug Enforcement
11 Administration controlled substance registration number of the dispensing pharmacy or the
12 dispensing physician or dentist;

13 (2) The full legal name, address and birth date of the person for whom the prescription is
14 written;

15 (3) The name, address and Drug Enforcement Administration controlled substances
16 registration number of the practitioner writing the prescription;

17 (4) The name and national drug code number of the Schedule II, III and IV controlled
18 substance or opioid antagonist dispensed;

19 (5) The quantity and dosage of the Schedule II, III and IV controlled substance or opioid
20 antagonist dispensed;

21 (6) The date the prescription was written and the date filled;

22 (7) The number of refills, if any, authorized by the prescription;

23 (8) If the prescription being dispensed is being picked up by someone other than the
24 patient on behalf of the patient, the first name, last name and middle initial, address and birth date
25 of the person picking up the prescription as set forth on the person's government-issued photo
26 identification card shall be retained in either print or electronic form until such time as otherwise
27 directed by rule promulgated by the ~~board~~ Board of Pharmacy; and

28 (9) The source of payment for the controlled substance dispensed.

29 (b) Whenever a medical services provider treats a patient and an overdose has occurred
30 or is suspected as a result of illicit or prescribed medication, the medical service provider shall
31 report the full legal name, address and birth date of the person for whom treatments for an

32 overdose or suspected overdose is provided, including any known ancillary evidence of the
33 overdose or suspected overdose including, but not limited to, the source of the overdose or
34 potential overdose, if known, any family history of substance use, positive drugs' screens and any
35 other evidence of the overdose or suspected overdose.

36 ~~(b)~~ (c) The ~~board~~ Board of Pharmacy may prescribe by rule promulgated ~~under this~~
37 pursuant to this article the form to be used in prescribing a Schedule II, III, and IV substance or
38 opioid antagonist if, in the determination of the ~~board~~ Board of Pharmacy, the administration of
39 the requirements of this section would be facilitated.

40 ~~(e)~~ (d) Products regulated by the provisions of article ten of this chapter shall be subject
41 to reporting pursuant to the provisions of this article to the extent set forth in said article.

42 ~~(d)~~ (e) Reporting required by this section is not required for a drug administered directly to
43 a patient by a practitioner. Reporting is, however, required by this section for a drug dispensed to
44 a patient by a practitioner. ~~Provided, That the~~ The quantity dispensed by a prescribing practitioner
45 to his or her own patient may not exceed an amount adequate to treat the patient for a maximum
46 of seventy-two hours with no greater than two 72-hour cycles dispensed in any fifteen-day period
47 of time.

48 ~~(e)~~ (f) The Board of Pharmacy shall notify a physician prescribing buprenorphine or
49 buprenorphine/naloxone within sixty days of the availability of ~~the~~ an abuse deterrent form of
50 buprenorphine or buprenorphine/naloxone ~~is~~ if approved by the Food and Drug Administration
51 as provided in FDA Guidance to Industry. Upon receipt of the notice, a physician may switch
52 their patients using buprenorphine or buprenorphine/naloxone to the abuse deterrent form of the
53 drug.

**§60A-9-5. Confidentiality; limited access to records; period of retention; no civil liability
for required reporting.**

1 (a)(1) The information required by this article to be kept by the ~~board~~ Board of Pharmacy
2 is confidential and not subject to the provisions of chapter twenty-nine-b of this code or obtainable

3 as discovery in civil matters absent a court order and is open to inspection only by inspectors and
4 agents of the ~~board~~ Board of Pharmacy, members of the West Virginia State Police expressly
5 authorized by the Superintendent of the West Virginia State Police to have access to the
6 information, authorized agents of local law-enforcement agencies as members of a federally
7 affiliated drug task force, authorized agents of the federal Drug Enforcement Administration, duly
8 authorized agents of the Bureau for Medical Services, duly authorized agents of the Office of the
9 Chief Medical Examiner for use in post-mortem examinations, duly authorized agents of the Office
10 of Health Facility Licensure and Certification and regulation of health facilities, duly authorized
11 agents of licensing boards of practitioners in this state and other states authorized to prescribe
12 Schedules II, III and IV controlled substances, prescribing practitioners and pharmacists, a dean
13 of any medical school or his or her designee located in this state to access prescribed level data
14 to monitor prescribing practices of faculty members, prescribers and residents enrolled in a
15 degree program at the school where he or she serves as dean, a physician reviewer designated
16 by an employer of medical providers to monitor prescriber level information of prescribing
17 practices of physicians, advance practice registered nurses or physician assistant in their employ,
18 and a chief medical officer of a hospital or a physician designated by the chief executive officer of
19 a hospital who does not have a chief medical officer, for prescribers who have admitting privileges
20 to the hospital or prescriber level information, and persons with an enforceable court order or
21 regulatory agency administrative subpoena. ~~Provided, That all~~ All law-enforcement personnel
22 who have access to the Controlled Substances Monitoring Program database shall be granted
23 access in accordance with applicable state laws and the ~~board's legislative~~ Board of Pharmacy's
24 rules, shall be certified as a West Virginia law-enforcement officer and shall have successfully
25 completed training approved by the ~~board~~ Board of Pharmacy. All information released by the
26 ~~board~~ Board of Pharmacy must be related to a specific patient or a specific individual or entity
27 under investigation by any of the above parties except that practitioners who prescribe or
28 dispense controlled substances may request specific data related to their Drug Enforcement

29 Administration controlled substance registration number or for the purpose of providing treatment
30 to a patient: *Provided*, That the West Virginia Controlled Substances Monitoring Program
31 Database Review Committee established in subsection (b) of this section is authorized to query
32 the database to comply with said subsection.

33 (2) Subject to the provisions of subdivision (1) of this subsection, the ~~board~~ Board of
34 Pharmacy shall also review the West Virginia Controlled Substance Monitoring Program database
35 and issue reports that identify abnormal or unusual practices of patients who exceed parameters
36 as determined by the advisory committee established in this section. The ~~board~~ Board of
37 Pharmacy shall communicate with practitioners and dispensers to more effectively manage the
38 medications of their patients in the manner recommended by the advisory committee. All other
39 reports produced by the ~~board~~ Board of Pharmacy shall be kept confidential. The ~~board~~ Board of
40 Pharmacy shall maintain the information required by this article for a period of not less than five
41 years. Notwithstanding any other provisions of this code to the contrary, data obtained under the
42 provisions of this article may be used for compilation of educational, scholarly or statistical
43 purposes, and may be shared with the West Virginia Department of Health and Human Resources
44 for those purposes, as long as the identities of persons or entities and any personally identifiable
45 information, including protected health information, contained therein shall be redacted, scrubbed
46 or otherwise irreversibly destroyed in a manner that will preserve the confidential nature of the
47 information. No individual or entity required to report under section four of this article may be
48 subject to a claim for civil damages or other civil relief for the reporting of information to the ~~board~~
49 Board of Pharmacy as required under and in accordance with the provisions of this article.

50 (3) The ~~board~~ Board of Pharmacy shall establish an advisory committee to develop,
51 implement and recommend parameters to be used in identifying abnormal or unusual usage
52 patterns of patients in this state. This advisory committee shall:

53 (A) Consist of the following members: A physician licensed by the West Virginia Board of
54 Medicine, a dentist licensed by the West Virginia Board of Dental Examiners, a physician licensed

55 by the West Virginia Board of Osteopathic Medicine, a licensed physician certified by the
56 American Board of Pain Medicine, a licensed physician board certified in medical oncology
57 recommended by the West Virginia State Medical Association, a licensed physician board
58 certified in palliative care recommended by the West Virginia Center on End of Life Care, a
59 pharmacist licensed by the West Virginia Board of Pharmacy, a licensed physician member of the
60 West Virginia Academy of Family Physicians, an expert in drug diversion and such other members
61 as determined by the ~~board~~ Board of Pharmacy.

62 (B) Recommend parameters to identify abnormal or unusual usage patterns of controlled
63 substances for patients in order to prepare reports as requested in accordance with subdivision
64 (2), subsection (a) of this section.

65 (C) Make recommendations for training, research and other areas that are determined by
66 the committee to have the potential to reduce inappropriate use of prescription drugs in this state,
67 including, but not limited to, studying issues related to diversion of controlled substances used for
68 the management of opioid addiction.

69 (D) Monitor the ability of medical services providers, health care facilities, pharmacists and
70 pharmacies to meet the 24-hour reporting requirement for the Controlled Substances Monitoring
71 Program set forth in section three of this article, and report on the feasibility of requiring real-time
72 reporting.

73 (E) Establish outreach programs with local law enforcement to provide education to local
74 law enforcement on the requirements and use of the Controlled Substances Monitoring Program
75 database established in this article.

76 (b) The ~~board~~ Board of Pharmacy shall create a West Virginia Controlled Substances
77 Monitoring Program Database Review Committee of individuals consisting of two prosecuting
78 attorneys from West Virginia counties, two physicians with specialties which require extensive
79 use of controlled substances and a pharmacist who is trained in the use and abuse of controlled
80 substances. The review committee may determine that an additional physician who is an expert

81 in the field under investigation be added to the team when the facts of a case indicate that the
82 additional expertise is required. The review committee, working independently, may query the
83 database based on parameters established by the advisory committee. The review committee
84 may make determinations on a case-by-case basis on specific unusual prescribing or dispensing
85 patterns indicated by outliers in the system or abnormal or unusual usage patterns of controlled
86 substances by patients which the review committee has reasonable cause to believe necessitates
87 further action by law enforcement or the licensing board having jurisdiction over the practitioners
88 or dispensers under consideration. The licensing board having jurisdiction over the practitioner or
89 dispenser under consideration shall report back to the Board of Pharmacy regarding any findings,
90 investigation or discipline resulting from the findings of the review committee within thirty days of
91 resolution of any action taken by the licensing board resulting from the information provided by
92 the Board of Pharmacy. The review committee shall also review notices provided by the chief
93 medical examiner pursuant to subsection (h), section ten, article twelve, chapter sixty-one of this
94 code and determine on a case-by-case basis whether a practitioner who prescribed or dispensed
95 a controlled substance resulting in or contributing to the drug overdose may have breached
96 professional or occupational standards or committed a criminal act when prescribing the
97 controlled substance at issue to the decedent. Only in those cases in which there is reasonable
98 cause to believe a breach of professional or occupational standards or a criminal act may have
99 occurred, the review committee shall notify the appropriate professional licensing agency having
100 jurisdiction over the applicable practitioner or dispenser and appropriate law-enforcement
101 agencies and provide pertinent information from the database for their consideration. The number
102 of cases identified shall be determined by the review committee based on a number that can be
103 adequately reviewed by the review committee. The information obtained and developed may not
104 be shared except as provided in this article and is not subject to the provisions of chapter
105 twenty-nine-b of this code or obtainable as discovering in civil matters absent a court order.

106 (c) The ~~board~~ Board of Pharmacy is responsible for establishing and providing
107 administrative support for the advisory committee and the West Virginia Controlled Substances
108 Monitoring Program Database Review Committee. The advisory committee and the review
109 committee shall elect a chair by majority vote. Members of the advisory committee and the review
110 committee may not be compensated in their capacity as members but shall be reimbursed for
111 reasonable expenses incurred in the performance of their duties.

112 (d) The ~~board~~ Board of Pharmacy shall promulgate rules with advice and consent of the
113 advisory committee, in accordance with the provisions of article three, chapter twenty-nine-a of
114 this code. The legislative rules must include, but shall not be limited to, the following matters:

115 (1) Identifying parameters used in identifying abnormal or unusual prescribing or
116 dispensing patterns;

117 (2) Processing parameters and developing reports of abnormal or unusual prescribing or
118 dispensing patterns for patients, practitioners and dispensers;

119 (3) Establishing the information to be contained in reports and the process by which the
120 reports will be generated and disseminated; and

121 (4) Setting up processes and procedures to ensure that the privacy, confidentiality, and
122 security of information collected, recorded, transmitted and maintained by the review committee
123 is not disclosed except as provided in this section.

124 (e) Persons or entities with access to the West Virginia Controlled Substances Monitoring
125 Program database pursuant to this section may, pursuant to rules promulgated by the ~~board~~
126 Board of Pharmacy, delegate appropriate personnel to have access to said database.

127 (f) Good faith reliance by a practitioner on information contained in the West Virginia
128 Controlled Substances Monitoring Program database in prescribing or dispensing or refusing or
129 declining to prescribe or dispense a Schedule II, III, or IV controlled substance shall constitute an
130 absolute defense in any civil or criminal action brought due to prescribing or dispensing or refusing
131 or declining to prescribe or dispense.

132 (g) A prescribing or dispensing practitioner may notify law enforcement of a patient who,
133 in the prescribing or dispensing practitioner's judgment, may be in violation of section four
134 hundred ten, article four of this chapter, based on information obtained and reviewed from the
135 controlled substances monitoring database. A prescribing or dispensing practitioner who makes
136 a notification pursuant to this subsection is immune from any civil, administrative or criminal
137 liability that otherwise might be incurred or imposed because of the notification if the notification
138 is made in good faith.

139 (h) Nothing in the article may be construed to require a practitioner to access the West
140 Virginia Controlled Substances Monitoring Program database except as provided in section five-a
141 of this article.

142 (i) The ~~board~~ Board of Pharmacy shall provide an annual report on the West Virginia
143 Controlled Substance Monitoring Program to the Legislative Oversight Commission on Health
144 and Human Resources Accountability with recommendations for needed legislation no later than
145 January 1 of each year.

**§60A-9-5a. Practitioner requirements to access database and conduct annual search of the
database; required rulemaking.**

1 (a) All practitioners, as that term is defined in section one hundred one, article two of this
2 chapter who prescribe or dispense Schedule II, III or IV controlled substances shall register with
3 the West Virginia Controlled Substances Monitoring Program and obtain and maintain online or
4 other electronic access to the program database: *Provided*, That compliance with the provisions
5 of this subsection must be accomplished within thirty days of the practitioner obtaining a new
6 license: *Provided, however*, That ~~no licensing board~~ the Board of Pharmacy may renew a
7 practitioner's license without proof that the practitioner meet the requirements of this subsection.

8 (b) Upon initially prescribing or dispensing any pain-relieving controlled substance for a
9 patient for whom they are providing pain-relieving controlled substances as part of a course of
10 treatment for chronic, nonmalignant pain but who are not suffering from a terminal illness and at

11 least annually thereafter should the practitioner or dispenser continue to treat the patient with
12 controlled substances, all persons with prescriptive or dispensing authority and in possession of
13 a valid Drug Enforcement Administration registration identification number and, who are licensed
14 by the Board of Medicine as set forth in article three, chapter thirty of this code, the Board of
15 Registered Professional Nurses as set forth in article seven of said chapter, the Board of Dental
16 Examiners as set forth in article four of said chapter and the Board of Osteopathic Medicine as
17 set forth in article fourteen of said chapter shall access the West Virginia Controlled Substances
18 Monitoring Program database for information regarding specific patients ~~for whom they are~~
19 ~~providing pain-relieving controlled substances as part of a course of treatment for chronic,~~
20 ~~nonmalignant pain but who are not suffering from a terminal illness.~~ The information obtained
21 from accessing the West Virginia Controlled Substances Monitoring Program database for the
22 patient shall be documented in the patient's medical record maintained by a private prescriber or
23 any inpatient facility licensed pursuant to the provisions of chapter sixteen of this code. A pain-
24 relieving controlled substance shall be defined as set forth in section one, article three-a, chapter
25 thirty of this code.

26 (c) The various boards mentioned in subsection (b) of this section shall promulgate both
27 emergency and legislative rules pursuant to the provisions of article three, chapter twenty-nine-a
28 of this code to effectuate the provisions of this section.

§60A-9-9. Drugs of concern designation.

1 (a) The Board of Pharmacy may designate certain drugs as drugs of concern which must
2 be reported to the database established pursuant to this article. The designation of a drug of
3 concern shall be reserved for drugs which have a high potential for abuse. Whenever a medical
4 services provider dispenses a drug of concern or whenever a prescription for a drug of concern
5 is filled by: (i) A pharmacist or pharmacy in this state; (ii) a hospital, or other health care facility,
6 for outpatient use; or (iii) a pharmacy or pharmacist licensed by the Board of Pharmacy, but
7 situated outside this state for delivery to a person residing in this state, the medical services

8 provider, health care facility, pharmacist or pharmacy shall, in a manner prescribed by rules
9 promulgated by the Board of Pharmacy under this article, report the following information, as
10 applicable:

11 (1) The name, address, pharmacy prescription number and Drug Enforcement
12 Administration controlled substance registration number of the dispensing pharmacy or the
13 dispensing physician or dentist;

14 (2) The full legal name, address and birth date of the person for whom the prescription is
15 written;

16 (3) The name, address and Drug Enforcement Administration controlled substances
17 registration number of the practitioner writing the prescription;

18 (4) The name and national drug number of the drug of concern dispensed;

19 (5) The quantity and dosage of the drug of concern dispensed;

20 (6) The date the prescription was written and the date filled;

21 (7) The number of refills, if any, authorized by the prescription;

22 (8) If the prescription being dispensed is being picked up by someone other than the
23 patient on behalf of the patient, the first name, last name and middle initial, address and birth date
24 of the person picking up the prescription as set forth on the person's government-issued photo
25 identification card shall be retained in either print or electronic form until such time as otherwise
26 directed by rule promulgated by the Board of Pharmacy; and

27 (9) The source of payment for the drug of concern dispensed.

28 (b) The penalties set forth in section seven of this article shall not apply to drugs listed as
29 drugs of concern. Failure to report may be considered a violation of the practice act of the
30 prescriber and may result in discipline by the appropriate licensing board.

31 (c) The Board of Pharmacy may promulgate emergency rules pursuant to the provisions
32 of section fifteen, article three, chapter twenty-nine-a of this code to effectuate the provisions of
33 this section.